Biotech Values

[dumaflotchie]

This makes the FoB-partnership negotiations rather different than they would be if MNTA were primarily looking for cash

If we look at the lovenox deal, they are getting 50/50 deal.

So we are presuming that they seek even better terms with the next prospect?

What is realistic in that sense....90/10, 60/40?

It does seem that they would require substantial assistance in production, marketing, distribution, etc......expetise that they do not presently have. These items are very capital intensive and could be a substantial drain on resources if they have a couple bad drug candiates.

But then again.....capoxone approval would put them in a whole new league ;)